Assessment of drug-drug interaction potential with EDP‐305, a farnesoid X receptor agonist, in healthy subjects
Abstract EDP‐305 is a farnesoid X receptor (FXR) agonist that selectively activates FXR and is a potential treatment for patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. Results from preclinical studies indicate that CYP3A4 is the primary enzyme involved in EDP‐305 metabolism a...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Wiley,
2022-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|